Terminated PHASE2 INTERVENTIONAL 1-arm NCT03350178

Evaluation of Heterologous Fecal microbiotA Transfer in ICU Patients: a FeasibilitY and SafetY StudY (HAPY3)

Sponsor: MaaT Pharma

Conditions Fecal Microbiota Transplantation Intensive Care Units

Updated 8 times since 2017 Last updated: Mar 6, 2019 Started: Jan 15, 2018 Primary completion: Feb 19, 2019 Completion: Feb 19, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

recruitment shortened

This PHASE2 trial investigates Fecal Microbiota Transplantation and Intensive Care Units and is currently terminated or withdrawn. MaaT Pharma leads this study, which shows 8 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Apr 2019 — Jan 2021 [monthly]

Terminated PHASE2

Status: Recruiting → Terminated
Sep 2018 — Apr 2019 [monthly]

Recruiting PHASE2

▶ Show 3 earlier versions

Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE2
Mar 2018 — Jun 2018 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2017 — Mar 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MaaT Pharma

Data source: MaaT Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lille, France
• Paris, France